NASDAQ:ADAG Adagene (ADAG) Stock Price, News & Analysis $2.52 -0.01 (-0.40%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.52▼$2.5850-Day Range$2.51▼$3.1052-Week Range$1.10▼$4.38Volume5,787 shsAverage Volume64,299 shsMarket Capitalization$111.28 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Adagene alerts: Email Address Adagene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside98.4% Upside$5.00 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.75) to ($1.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.78 out of 5 starsMedical Sector457th out of 936 stocksPharmaceutical Preparations Industry209th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAdagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdagene has only been the subject of 1 research reports in the past 90 days.Read more about Adagene's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently decreased by 62.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAG. Previous Next 2.8 News and Social Media Coverage News SentimentAdagene has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Adagene this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Adagene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.51% of the stock of Adagene is held by institutions.Read more about Adagene's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adagene are expected to decrease in the coming year, from ($0.75) to ($1.14) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Adagene Stock (NASDAQ:ADAG)Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Read More ADAG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAG Stock News HeadlinesJuly 26 at 2:16 AM | americanbankingnews.comShort Interest in Adagene Inc. (NASDAQ:ADAG) Decreases By 62.9%July 23 at 5:44 AM | markets.businessinsider.comBuy Rating on Adagene: Market Advantage and Promising Clinical Trials Fuel Growth PotentialJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 22, 2024 | americanbankingnews.comAdagene (NASDAQ:ADAG) Receives "Buy" Rating from HC WainwrightJuly 19, 2024 | morningstar.comAdagene Inc ADR ADAGJuly 12, 2024 | globenewswire.comAdagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in SeptemberMay 22, 2024 | globenewswire.comAdagene to Present at Investor Conferences in JuneApril 10, 2024 | investing.comMorgan Stanley lifts Adagene stock target on positive dataJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.March 31, 2024 | finanznachrichten.deAdagene Inc.: Adagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | globenewswire.comAdagene Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 7, 2024 | globenewswire.comAdagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardFebruary 27, 2024 | globenewswire.comAdagene to Present at the Leerink Partners Global Biopharma Conference 2024February 9, 2024 | finance.yahoo.comAdagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)January 21, 2024 | seekingalpha.comWeek In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure TherapyJanuary 19, 2024 | msn.comMesoblast rises after cell therapy gets FDA rare pediatric disease designationJanuary 18, 2024 | benzinga.comHow Is The Market Feeling About Adagene?January 17, 2024 | realmoney.thestreet.comMorgan Stanley 'encouraged' by 2 cPRs reported by AdageneSee More Headlines Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAG CUSIPN/A CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+98.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.19 Current Ratio3.61 Quick Ratio3.61 Sales & Book Value Annual Sales$18.11 million Price / Sales6.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book1.57Miscellaneous Outstanding Shares44,157,000Free Float34,796,000Market Cap$111.28 million OptionableNot Optionable Beta0.65 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Peter P. Luo Ph.D. (Age 58)Co- Founder, Chairman, CEO and President of R&D Mr. Man Kin Tam M.B.A. (Age 47)CFO & Director Dr. Jc Xu M.D. (Age 59)Ph.D., Chief Scientific Officer Ms. Ami Celeste KnoeflerVice President of Investor Relations & Corporate CommunicationsMs. Ling ZhouHead of Human ResourcesDr. Qinghai Zhao (Age 63)Chief Manufacturing Officer Ms. Yan Li M.B.A. (Age 49)Senior VP of Bioinformatics & Information Technology and Director Ms. Xiaohong She (Age 57)Senior VP & Head of Clinical Operations Dr. Guizhong Liu Ph.D. (Age 53)Senior Vice President of Early Drug Discovery Mr. Alexander Goergen (Age 37)VP & Head of Business Development More ExecutivesKey CompetitorsCompugenNASDAQ:CGENInnate PharmaNASDAQ:IPHAXilio TherapeuticsNASDAQ:XLOCue BiopharmaNASDAQ:CUEMEI PharmaNASDAQ:MEIPView All CompetitorsInstitutional OwnershipCatalina Capital Group LLCBought 16,752 shares on 7/24/2024Ownership: 0.038%Artal Group S.A.Bought 20,000 shares on 5/17/2024Ownership: 2.312%WuXi AppTec Co. Ltd.Sold 242,794 shares on 5/7/2024Ownership: 9.027%View All Institutional Transactions ADAG Stock Analysis - Frequently Asked Questions How have ADAG shares performed this year? Adagene's stock was trading at $1.9314 at the start of the year. Since then, ADAG shares have increased by 30.5% and is now trading at $2.52. View the best growth stocks for 2024 here. When did Adagene IPO? Adagene (ADAG) raised $133 million in an initial public offering on Tuesday, February 9th 2021. The company issued 7,400,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager. Who are Adagene's major shareholders? Top institutional investors of Adagene include Catalina Capital Group LLC (0.04%). How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADAG) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
